The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) program attempted to determine whether some treatment sequences are better than others in the management of depression. Application of the findings to UK treatment settings is difficult because depression is an inhomogeneous condition and to regard it as a unitary entity, to which a unitary stratagem can be applied, is possibly misguided.
Bauer MDopfmer S (1999) Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol19: 427-434.
2.
Berman RMMarcus RNSwanink RMcQuade RDCarson WHCorey-Lisle PK (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind placebo-controlled study. J Clin Psychiatry68: 843-853.
3.
Deakin JO'Loughlin C (2009) STAR*D: a summary and UK perspective. J Psychopharm23: 605-612.
4.
Kirsch IDeacon BJHuedo-Medina TBScoboria AMoore TJJohnson BT (2008) Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med5: e45. doi: 10.1371/journal.pmed.0050045.
5.
Malt UFRobak OHMadsbu HPBakke OLoeb M (1999) The Norwegian Naturalistic Treatment Study of Depression in General Practice (NORDEP)-I: randomised double blind study. BMJ318: 1180-1184.
6.
National Institute for Clinical Excellence (2004) Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline 23.London: NICE.
7.
Papakostas GShelton RCSmith JFava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry68: 826-831.
8.
Papakostas GIFava MThase ME (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry63: 699-704.
